Previous network meta-analysis assessed efficacy and safety of different targeted therapies in patients with active RA in distinct settings of inadequate response to MTX or anti-TNF agents, comparing biosimilar to its originator [41,42], or comparing different Jak-inhibitors [43], using MTX as common comparator. The gene discussed is TNF; the disease is rheumatoid arthritis.